Cedar Hill Associates LLC lowered its stake in UnitedHealth Group Inc (NYSE:UNH) by 2.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 49,674 shares of the healthcare conglomerate’s stock after selling 1,416 shares during the period. UnitedHealth Group accounts for 1.7% of Cedar Hill Associates LLC’s portfolio, making the stock its 22nd largest position. Cedar Hill Associates LLC’s holdings in UnitedHealth Group were worth $9,728,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also made changes to their positions in the company. Blue Chip Partners Inc. bought a new position in shares of UnitedHealth Group during the second quarter worth $110,000. Bruderman Asset Management LLC bought a new position in shares of UnitedHealth Group during the second quarter worth $114,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its position in shares of UnitedHealth Group by 433.3% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 640 shares of the healthcare conglomerate’s stock worth $119,000 after purchasing an additional 520 shares in the last quarter. BDO Wealth Advisors LLC bought a new position in shares of UnitedHealth Group during the second quarter worth $121,000. Finally, Acrospire Investment Management LLC boosted its position in shares of UnitedHealth Group by 130.7% during the second quarter. Acrospire Investment Management LLC now owns 706 shares of the healthcare conglomerate’s stock worth $131,000 after purchasing an additional 400 shares in the last quarter. 86.00% of the stock is currently owned by hedge funds and other institutional investors.
UNH has been the topic of several research reports. Zacks Investment Research raised shares of UnitedHealth Group from a “hold” rating to a “buy” rating and set a $267.00 price objective on the stock in a research report on Saturday, January 20th. Goldman Sachs Group initiated coverage on shares of UnitedHealth Group in a research report on Wednesday, January 3rd. They issued a “buy” rating and a $269.00 price objective on the stock. Morgan Stanley boosted their price objective on shares of UnitedHealth Group from $215.00 to $235.00 and gave the company an “overweight” rating in a research report on Wednesday, October 18th. Credit Suisse Group boosted their price objective on shares of UnitedHealth Group from $252.00 to $260.00 and gave the company an “outperform” rating in a research report on Wednesday, January 17th. Finally, Leerink Swann reaffirmed a “buy” rating and issued a $240.00 price objective (up from $225.00) on shares of UnitedHealth Group in a research report on Wednesday, October 18th. Two equities research analysts have rated the stock with a hold rating and twenty-six have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $243.22.
UnitedHealth Group (NYSE:UNH) last released its quarterly earnings data on Tuesday, January 16th. The healthcare conglomerate reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.09. The company had revenue of $52.06 billion for the quarter, compared to analyst estimates of $51.57 billion. UnitedHealth Group had a net margin of 5.25% and a return on equity of 21.29%. UnitedHealth Group’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the previous year, the business earned $2.11 EPS. sell-side analysts anticipate that UnitedHealth Group Inc will post 12.51 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 20th. Investors of record on Friday, March 9th will be issued a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a dividend yield of 1.33%. UnitedHealth Group’s payout ratio is 31.58%.
In related news, Director Michele J. Hooper sold 5,000 shares of UnitedHealth Group stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $222.20, for a total transaction of $1,111,000.00. Following the completion of the sale, the director now owns 36,989 shares of the company’s stock, valued at approximately $8,218,955.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gail R. Wilensky sold 5,600 shares of UnitedHealth Group stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $223.31, for a total transaction of $1,250,536.00. Following the sale, the director now directly owns 61,137 shares of the company’s stock, valued at approximately $13,652,503.47. The disclosure for this sale can be found here. Insiders have sold a total of 53,396 shares of company stock valued at $12,262,067 in the last ninety days. 0.89% of the stock is currently owned by insiders.
WARNING: This report was first published by Week Herald and is owned by of Week Herald. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://weekherald.com/2018/02/15/cedar-hill-associates-llc-has-9-73-million-holdings-in-unitedhealth-group-inc-unh.html.
About UnitedHealth Group
UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.